Vital Therapies, a clinical-stage biotech developing treatments for acute liver failure, revived its IPO by filing an amended S-1 with the SEC on Friday. The company had previously launched a deal to raise $75 million by selling 4.4 million shares at $16 to $18 per share but postponed on November 21, 2013. The company's updated filing removed the original IPO terms.
The San Diego, CA-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol VTL. BofA Merrill Lynch and Credit Suisse are the joint bookrunners on the deal.
